Privately-held Singapore-based company Tessa Therapeutics’ CD30-directed autologous CAR-T therapy has received US Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation.
GlobalData has predicted that the drug, which is known only as TT11, will become the leading cell-based therapy in Hodgkin’s lymphoma (HL), and will displace stem cell transplants as the standard of care by 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze